Baricitinib was approved by the U.S. FDA as a selective JAK1 and JAK2 inhibitor for the indications of rheumatoid arthritis and Coronavirus Disease 2019 (COVID-19) but not yet for atopic dermatitis (125). The gene discussed is JAK1; the disease is rheumatoid arthritis.